Super Biotechs of last
6 months The chemical reactions that produce energy.
New Drug Applications
FDA Press Announcements
TigerSoft Blog - AMGEN's 1990-1991 Take Off Remembered 9/6/2007
TigerSoft Blog - Biotech's Game of Roulette: Bullish Signs 9-21-2007/
January 17, 2014 - FDA allows marketing for first of-its-kind post-natal test to help diagnose
developmental delays and intellectual disabilities in children
http://www.affymetrix.com/
January 08, 2014 - FDA approves Farxiga to treat type 2 diabetes AstraZeneca
--------------------------------------------------------------------------------------------------------------------------
The research I've done on the way the strongest stocks topped
out in 1999-2000 shows several things:
1) Weekly OBV non-confirmations of new highs gave the
most timely Sells on these stocks. I will be posting weekly
data on all the strongest biotechs on our data page. It
will be included in the regularly weekly data.
2) Many of the 1999-2000 stocks were up 8x-10x their 12-month
lows.
3) 25% were more than 48% above their 21-day ma.
4) Closing Power trend-breaks in the very strongest stocks
was the most common way one could have know that a
top had been made.
5) In the daily charts, Closing Power NCs and OBV NCs occurred
at 1/2 the tops.
6) Head and shoulders in the daily charts appreared In 1/4 of
the 1999-2000 super stocks as they were topping out.
7) False breakouts occurred in 1/4 of the these stocks.
8) The declines that resulted were swift and punishing to the
longs who ignored them. 30%-50% declines within three months
were the norm. Some were even more severe.
Biotechs over $5 that are up 220% or more
1/22/2014 130-day pct change
This allows better comparisons with 1999-2000 study.
------------------------------------------------------------------------------------
----->BCRX 1214 +519% channel breakout
13.53 is 5-year high - OBV confirming.
BioCryst Pharmaceuticals 40 employees Durham, NC http://www.biocryst.com
- develops novel drugs that block key enzymes involved in the pathogenesis of diseases.
- in Phase III clinical trials for acute influenza;
IDRA 4.14 +478% low IP21/ Falling CP
------>ARWR 11.99 +399% on channel breakout run
All-time high. OBV is confirming.
Arrowhead Research Corp. 54 employees http://www.arrowheadresearch.com
ARC-520, an RNAi-based therapeutic that has completed a Phase 1 clinical trial for the
treatment of chronic hepatitis B virus (HBV) infection; and
Adipotide, which is in Phase I clinical trial for the treatment for obesity.
ICPT 326.11 +560%
GALE 6.38 +250% Red distribution. CP weak. OBV H/S pattern.
ANAC 20.76 +224% Channel Breakout. Above 20 legitimizes it
for some institutions.
Wkly OBV confirming. Both UP condition.
Focuses on discovering, developing, and commercializing novel small-molecule
therapeutics derived from its boron chemistry platform. The company's lead product
candidates include tavaborole, an antifungal product candidate that is in Phase III
clinical development for the treatment of onychomycosis; and AN2728, an
anti-inflammatory product candidate, which completed Phase II clinical trials
for the treatment of atopic dermatitis and psoriasis
Anacor Pharmaceuticals Inc: The Best Performing Biotechs of 2013
An Eczema Stock That Keeps Breaking Ou
Anacor Pharmaceuticals Is Not for Everyon
